Advances and future challenges in non-Hodgkin's lymphoma

Current Opinion in Oncology

Volumn 10, Issue 5, 1998, Pages 422-427

  Klencke, Barbara ^a   Kaplan, Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 2; METHOTREXATE; PREDNISONE; RITOXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 0031761131     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199809000-00009     Document Type: Review

References (37)

1. Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992, 52(Suppl):5432s-5440s.
2. Biggar RJ, Rabkin CS: The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol 1992, 4:883-893.
3. Selik RM, Chu SY, Ward JW: Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 1995, 123:933-936.
4. Jones, JL, Hanson DL, Ward JW: Effect of antiretroviral therapy on recent trends in cancers among HIV-infected persons [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:S3.
5. Biggar RJ, Rosenberg PS, Cote T: Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996, 68:754-758.
6. Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy Y, Yellin FL, et al.: Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997, 73:645-650. AIDS and cancer registry linkage allows more precise estimates of incidence and relative risks, the ability to adjust for age, sex, and ethnicity, and to analyse for stage and histology.
7. Holly EA, Lele C: Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco bay area. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:211-222. Large population-based epidemiology study of NHL.
8. Holly EA, Lele C, Bracci P: Non-Hodgkin's lymphoma in homosexual men in the San Francisco bay area. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:223-231.
9. Feuillard J, Aubin JT, Poirel L, Davi F, Kujas M, Rousselet MC, et al.: Detection rate and intratumoral virus load of human herpesvirus-8 in immunodeficiency-related B-cell lymphoid malignancies. J Med Virol 1997, 53:277-281.
10. Hamilton-Dutoit SJ, Raphael M, Audouin J, Diebold J, Lisse I, Pedersen C, et al.: In situ demonstration of Epstein-Barr virus small RNAs (EBER1) in acquired immunodeficiency syndrome-related lymphomas: Correlation with tumor morphology and primary site. Blood 1993, 82:619-624.
11. Beral V, Petterman T, Berkelman R, Jaffe H: AIDS-associated non Hodgkin lymphoma. Lancet 1991, 337:805-809.
12. Ometto L, Menin C, Masiero S, Bonaldi L, Mistro AD, Cattelan AM, et al.: Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997, 90:313-322. Evidence based on heterogenous EBV populations in lymphadenopathy, but a more defined EBV population in lymphomas strengthens the etiologic role for EBV in lymphomagenesis in the setting of HIV.
13. Leibowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998, 338:1413-1421. An excellent overview and presentation of new findings regarding the pathogenesis of EBV-associated lymphomas.
14. Kersten MJ, Klein MR, Holwerda AM, Miedema F, van Oers HJ: Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection. J Clin Invest 1997, 99:1525-1533. Prospective evaluation of cellular immune function in a cohort of patients progressing to AIDS with opportunistic infection compared with those progressing to AIDS with NHL.
15. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, et al.: AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989, 261:719-724.
16. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, et al.: Human immunodeficiency virus-related lymphoma: prognostic factors predictive of survival. Cancer 1991, 68:2466-2472.
17. Gisselbrecht C, Okesenhendler E, Tirelli U, Lepage E, Gabarre J, Farcet JP, et al.: Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 1993, 95:188-196.
18. Vaccher E, Tirelli U, Spina M, Talamini R, Errante D, Simonelli C, Carbone A: Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients. J Clin Oncol 1996, 14:2217-2223.
19. Lowenthal DA, Straus DJ, Campbell SW, Gold JWM, Clarkson BD, Koziner B: AIDS-related lymphoid neoplasia: the Memorial Hospital experience. Cancer 1988, 61:2325-2337.
20. Kaplan LD, Shiramizu B, Herndier B, Hahn J, Meeker TC, Ng V, et al.: Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome. Blood 1995, 85:1727-1735.
21. Levine AM: Acquired immunodeficiency syndrome-related lymphoma. Blood 1992, 80:8-20.
22. Zieglar JL, Beckstead JA, Volberding PA, Abrams DI, Levine AM, Lukes RJ, et al.: Non-Hodgkin's lymphoma in 90 homosexual men: relation to generalized lymphoadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984, 311:565-570.
23. Knowles DM, Chamulak G, Subar M, Burke JS, Dugan M, Wernz J, et al.: Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988, 108:744-753.
24. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Debuze BJ, Cooley TP, et al.: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997, 336:1641-1648. Largest prospective intervention trial performed for HIV-related NHL Low dose therapy yielded equivalent outcome and was better tolerated than standard dose chemotherapy.
25. Vaccher E, Spina M, Talamini R, Lucenti A, Errante D, Tavio M, et al.: Concomitant CHOP chemotherapy and highly active antiretroviral therapy in patients with HIV-related non-Hodgkin's lymphoma [abstract]. Proc Am Soc Clin Oncol 1988, 17:184.
26. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, et al.: Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol 1996, 14:3026-3035. A promising, effective first line chemotherapy option for HIV-related NHL patients.
27. Kaplan LD, Moran T, Song L, Tuan B, Northfelt D: Continuous infusion Ifosfamide/Mesna with daily etoposide for refractory HIV-associated non-Hodgkin's lymphoma [abstract]. Proc Am Soc Clin Oncol 1998, 17:185.
28. Tirelli U, Errante D, Spina M, Gastaldi R, Nigra E, Nosari AM, et al.: Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma. Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer 1996, 77:2127-2131.
29. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, et al.: Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995, 86:3287-3294.
30. Khatri VP, Baiocchi RA, Berstein ZP, Caligiuri MA: Immunotherapy with low-dose mterleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997, 3:S128-S136.
31. Link BK, Grossbard ML, Fisher RI, Czuczman M, Gilman P, Lowe AM, Vose JM: Phase II pilot study of the safety and efficacy of Rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL [abstract]. Proc Am Soc Clin Oncol 1998, 17:7.
32. Sparano JA, Hu X, Wiernik PH, Sarta C, Reddy DM, Hanau L, Henry DH: Opportunistic infection and immunologie function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J Nat Cancer Inst 1997, 89:301-307. NHL patients were matched for CD4 cell count at the initiation of chemotherapy with HIV patients without lymphoma. Subsequent CD4 cell counts and infectious complications followed for a year after the completion of chemotherapy.
33. Rutschmann OT, Pechere M, Krischer J, Perrin L, Hirschel B: Chemotherapy for AIDS-related malignancies does not increase HIV viraemia [letter]. AIDS 1997, 11:944-945.
34. Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, Rich WJ, Jacobson MA, and the G-CSF 930101 Study Group: Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 1998, 12:65-73. Randomized trial of continuous, intermittent, or no growth factor support for those with moderate level neutropenia, unrelated to chemotherapy, at baseline.
35. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Seines OA, et al.: Temporal trends in the incidence of HIV-1 related neurologic diseases: multicenter AIDS cohort study, 1985-1992. Neurology 1994, 44:1892-1900.
36. Antinori A, Ammassari A, De Luca A, Cingolani A, Murri R, Scoppettuolo G, et al.: Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997, 48:687-694. Test characteristics described for a new method of diagnosing focal brain lesions in AIDS patients.
37. Baumgartner J, Rachlin RK, Beckstead JH, Meeker TC, Levy RM, Wara WM, Rosenblum ML: Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with the acquired immunodeficiency syndrome. J Neurosurg 1990, 73:206-211.